Estradiol administration for patients with a history of poor IVFresponse

Comparsion of luteal estradiol administration during GnRH antagonist protocol versus microdose GnRH agonist protocol for patients with a history of poor IVF out come

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108044339N8

Enrollment

116

Registered

2011-09-15

Start date

2011-03-01

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility. Female infertility

Interventions

Intervention 1: Fifty eight randomly selected women underwent IVF using the E2/antagonist protocol (E2/ANT group). In this group, estradiol (Aburaihan Pharmaceutical Co., Tehran, Iran) 2 mg was starte

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: A history of poor response in a prior cycle (=3 oocytes retrieved, poor-quality oocytes, Cycle cancellation due to inadequate ovarian response Women anticipated to be a poor responder based on initial testing (third-day FSH level of 10 mIU/mL, or a basal antral follicle count <5)

Exclusion criteria

Exclusion criteria: Stage III–IV endometriosis Autoimmune or chromosomal disorders Endocrine or metabolic diseases Existence of only one ovary Patients exhibiting a day 3 serum FSH level greater than 15 mIU/mL Sever male factor (patients with azoospermia and normal morphology of sperm <4%) Hydrosalpinx

Design outcomes

Primary

Measure	Time frame
The number of oocyte retrival. Timepoint: Day of punctuer. Method of measurement: Counting by microscope.;Clinical pregnancy rates. Timepoint: 5 weeks after the embryo transfer. Method of measurement: Presence of a gestational sac with heart beat identified byultrasound.	—

Secondary

Measure	Time frame
The cycle length. Timepoint: From the start of the drug until the day of the puncture. Method of measurement: Calendar.;The total dose of gonadotropin. Timepoint: From the start of the drug until the day of the puncture. Method of measurement: International unit.;The implantation rate. Timepoint: 5 weeks after the embryo transfer. Method of measurement: The number of pregnancy sacs divided by the number of transferred embryos multiplied by 100.	—

Measure

Time frame

The cycle length. Timepoint: From the start of the drug until the day of the puncture. Method of measurement: Calendar.;The total dose of gonadotropin. Timepoint: From the start of the drug until the day of the puncture. Method of measurement: International unit.;The implantation rate. Timepoint: 5 weeks after the embryo transfer. Method of measurement: The number of pregnancy sacs divided by the number of transferred embryos multiplied by 100.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mozhgan Rahsepar

Yazd Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences

drrahsepar@hotmail.com+98 35 1824 7085

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026